Investment entities affiliated with Samsara BioCapital and Srinivas Akkaraju reported beneficial ownership of Eloxx Pharmaceuticals, Inc. common stock. Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., and Samsara Opportunity Fund GP, LLC each report beneficial ownership of 201,793 shares, representing 5.0% of Eloxx’s common stock.
Dr. Srinivas Akkaraju reports beneficial ownership of 403,586 shares, or 9.99% of the common stock, based on 4,036,314 shares outstanding as of June 10, 2026. The position includes, for each of Samsara LP and Samsara Opportunity Fund, 200,000 shares of common stock and Pre-Funded Warrants exercisable for up to 250,000 shares, subject to a 9.99% Beneficial Ownership Blocker that limits warrant exercise above that ownership level.
"pre-funded warrants ("Pre-Funded Warrants") exercisable for up to 250,000 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Beneficial Ownership Blockerfinancial
"The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker")"
A beneficial ownership blocker is a legal or structural device that prevents a shareholder from being treated as the ultimate owner of enough shares to trigger control, reporting, or voting thresholds. Think of it like a speed bump that stops an investor from reaching a stake size that would force corporate disclosure or change control rights. Investors care because it affects who controls the company, how shares vote, regulatory filings, takeover risk and therefore potential value or liquidity of their holdings.
shared voting powerfinancial
"6 | Shared Voting Power 201,793.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerfinancial
"8 | Shared Dispositive Power 201,793.00"
FAQ
What stake in Eloxx Pharmaceuticals (ELOX) does Srinivas Akkaraju report?
Dr. Srinivas Akkaraju reports beneficial ownership of 403,586 shares of Eloxx common stock, representing 9.99% of the class, based on 4,036,314 shares outstanding as of June 10, 2026.
How many Eloxx (ELOX) shares do the Samsara BioCapital entities beneficially own?
Each Samsara BioCapital-related entity reports beneficial ownership of 201,793 shares of Eloxx common stock, representing 5.0% of the outstanding shares, with voting and dispositive power shared among the affiliated entities.
What securities do Samsara LP and Samsara Opportunity Fund hold in Eloxx (ELOX)?
Samsara LP and Samsara Opportunity Fund each directly hold 200,000 common shares and Pre-Funded Warrants exercisable for up to 250,000 additional shares of Eloxx common stock, subject to a Beneficial Ownership Blocker.
How is the percentage ownership in Eloxx (ELOX) calculated for these reporting persons?
The percentages are based on 4,036,314 Eloxx shares outstanding as of June 10, 2026, and give effect to Pre-Funded Warrants only to the extent exercisable within 60 days, consistent with beneficial ownership rules.
What is the Beneficial Ownership Blocker affecting Eloxx (ELOX) Pre-Funded Warrants?
The Pre-Funded Warrants include a 9.99% Beneficial Ownership Blocker, preventing exercise if it would cause the reporting persons, together with affiliates, to own more than 9.99% of Eloxx’s outstanding common stock.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Eloxx Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.01 par value per share
(Title of Class of Securities)
29014R301
(CUSIP Number)
06/10/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
29014R301
1
Names of Reporting Persons
Samsara BioCapital, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
201,793.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
201,793.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
201,793.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
29014R301
1
Names of Reporting Persons
Samsara BioCapital GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
201,793.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
201,793.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
201,793.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
29014R301
1
Names of Reporting Persons
Samsara Opportunity Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
201,793.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
201,793.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
201,793.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
29014R301
1
Names of Reporting Persons
Samsara Opportunity Fund GP, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
201,793.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
201,793.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
201,793.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
29014R301
1
Names of Reporting Persons
Srinivas Akkaraju
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
403,586.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
403,586.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
403,586.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Eloxx Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
P.O. Box 274, Arlington, MA, 02476.
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
Samsara BioCapital, L.P. ("Samsara LP")
Samsara BioCapital GP, LLC ("Samsara GP")
Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund")
Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP")
Srinivas Akkaraju ("Dr. Akkaraju")
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
(b)
Address or principal business office or, if none, residence:
Samsara LP Delaware
Samsara GP Delaware
Samsara Opportunity Fund Delaware
Samsara Opportunity GP Delaware
Dr. Akkaraju United States
(d)
Title of class of securities:
Common Stock, $0.01 par value per share
(e)
CUSIP Number(s):
29014R301
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
The Reporting Persons' beneficial ownership of the Issuer's securities includes: (i) 200,000 shares of common stock and pre-funded warrants ("Pre-Funded Warrants") exercisable for up to 250,000 shares of common stock directly held by Samsara LP and (ii) 200,000 shares of common stock and Pre-Funded Warrants exercisable for up to 250,000 shares of common stock directly held by Samsara Opportunity Fund. The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker"), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, the Reporting Persons, together with their affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding. By virtue of the Beneficial Ownership Blocker, each of Samsara LP and Samsara Opportunity Fund is currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in the Reporting Persons' beneficial ownership of more than 403,586 shares of common stock.
Samsara GP is the sole general partner of Samsara LP and Dr. Akkaraju is the managing member of Samsara GP. Each of Samsara GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara LP.
Samsara Opportunity GP is the sole general partner of Samsara Opportunity Fund and Dr. Akkaraju is the managing member of Samsara Opportunity GP. Each of Samsara Opportunity GP and Dr. Akkaraju possesses power to direct the voting and disposition of the securities held by Samsara Opportunity Fund.
(b)
Percent of class:
Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The percentage set forth in each row 11 is based upon 4,036,314 shares outstanding as of June 10, 2026, as reported in the Issuer's final prospectus dated June 8, 2026 filed with the Securities and Exchange Commission (the "SEC") on June 9, 2026, and giving effect to Pre-Funded Warrants, to the extent exercisable within 60 days hereof, as referenced herein.
Dr. Akkaraju beneficially owns 9.99% of the outstanding Class A common stock. Due to field limitations of the EDGAR filing system, the percentage listed in Row 11 of Dr. Akkaraju's cover page has been rounded down to 9.9%.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Samsara BioCapital, L.P.
Signature:
/s/ Srinivas Akkaraju
Name/Title:
By Samsara BioCapital GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member
Date:
08/14/2026
Samsara BioCapital GP, LLC
Signature:
/s/ Srinivas Akkaraju
Name/Title:
By Srinivas Akkaraju, Managing Member
Date:
08/14/2026
Samsara Opportunity Fund, L.P.
Signature:
/s/ Srinivas Akkaraju
Name/Title:
By Samsara Opportunity Fund GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member
